HLA-C and cardiac hypertrophy: In addition, the chronic administration of Theracurmin® (100 mg/kg/day gavage for 5 weeks) in the 5/6NX rat model improved ventricular function and avoided fatal consequences such as heart hypertrophy and interstitial fibrosis by reducing beta myosin heavy chain (ß-MHC) and Col I levels [160].